Peter Neumann

Director, @TuftsCEVR. Co-author, #therightpricebook.

[Peter Neumann @PeterNeumann11]

Everyone wants lower drug prices, but the critical question is not how to cut prices, but how to align prices with the value delivered. Our new book explains how. Available at Oxford Univ Press (https://t.co/fXLosiPk32) and Amazon (https://t.co/Ql7FoiI4Nj).

[Health Affairs @Health_Affairs]

We are excited to share the first article in a new Health Affairs Scholar series by the Center for the Evaluation of Value and Risk in Health (CEVR) at @TuftsMedicalCtr. The series focuses on “Value of Strategies to Improve Health Care." https://t.co/VpaIIYh28B

[Peter Neumann @PeterNeumann11]

Our new @HealthAffairs Forefront commentary asks whether #Medicare's IPAY 2027 negotiated drug prices reflect value for money.

https://t.co/uDOxJySgGq

[Peter Neumann @PeterNeumann11]

The best books I read in 2024. My annual list.

https://t.co/dPw4X0RgkX

@TuftsCEVR @peterbachmd @DusetzinaS @jonathaneig #books #BooksWorthReading

[Peter Neumann @PeterNeumann11]

The outlook for US payer coverage of specialty drugs in 2005.

Register here for our webinar, Dec 4, 3-3:30 ET: https://t.co/td7omRloxz

@jchambers241 @mollytoba @npcnow @brianreid #heor #biosimilars @TuftsCEVR

[CEVR @TuftsCEVR]

A cost-effective treatment for #Alzheimers would improve US population health and health equity. Read the new distributional CEA by CEVR and @genentech for data-driven insights on policies to further mitigate disparities.

https://t.co/s1BW8CCSKv

[CEVR @TuftsCEVR]

Small molecules and biologics are eligible for #IRA price negotiation 9 vs 13 years after approval. New CEVR research shows small molecules give similar health benefits at lower cost than biologics. Should IRA be reformed to set equivalent timelines?

https://t.co/V42ZxYlA1g

[Hanxuan (Astrid) Yu @hanxuan_yu]

Me presenting @socmdm ! So happy to work with @ashleyleech @ddkim62 @PeterNeumann11 🙌 It was wonderful to share our findings on CEA thresholds in cost-per-QALY studies worldwide based on @TuftsCEVR CEA registry at #SMDM24

[Peter Neumann @PeterNeumann11]

Thank you, @KathrynP_phd !

[Kathryn A Phillips PhD @KathrynP_phd]

So fun to be in Boston w/ #CEA leaders @TuftsCEVR @PeterNeumann11 & so many other leaders that I can't name them all. Wow look at the growth of CEAs! When I started in field were almost none & now there are thousands!

[Peter Neumann @PeterNeumann11]

Excited to have #SMDM24 meeting in Boston this year!

Amber Barnato and @JagChhatwal kicking things off.

@socmdm @TuftsCEVR

[Hanxuan (Astrid) Yu @hanxuan_yu]

I’ll also be presenting at the Cost-Effectiveness Thresholds Used in Cost-Per-QALY Studies on Tuesday at 3:50PM — Don’t miss it! 🙌 Grateful for the support from ⁦@ashleyleech⁩ ⁦@ddkim62⁩ ⁦@PeterNeumann11⁩ #SMDM24 #MDMTwitter

[Paige Lin @PaigeLin_HEOR]

✨💡Illuminators of cost-effectiveness analysis in health and medicine 💡✨ So inspired by the pioneers of #CEA who've shaped our field of study!
@TuftsCEVR @PeterNeumann11 @AnkurFactorial @PSynnott29 #CelebrateCEA

[Patricia Synnott @PSynnott29]

Which #HEOR superhero are you?

Looking forward to meeting many of my HEOR heroes at tomorrow’s symposium on cost-effectiveness analysis
#CelebrateCEA @TuftsCEVR

[Peter Neumann @PeterNeumann11]

Pleased to give Grand Rounds today at @TuftsMedicalCtr!

[CEVR @TuftsCEVR]

Drug value assessments are important, but economists shouldn't neglect assessment of health services and procedures.

Hear perspectives from CEVR's @PeterNeumann11, @RxEconomics, and EBRI's @pfronstin during Oct. 31 public webinar.

Register now: https://t.co/hfMr9EP4GJ

[Peter Neumann @PeterNeumann11]

The final agenda for the 10/26 symposium in Boston, "Celebrating CEA," is now available.

Panelists include: @Basucally, @contirena1, Emond, Garrison, Lakdawalla, Phelps, Weinstein, etc.

Register in person or online:
https://t.co/XaDi6ztmB0 @TuftsCEVR @DukeMargolis @socmdm

[Peter Neumann @PeterNeumann11]

Excited to announce that Milton Weinstein will join the "legends" panel at the 10/26 @TuftsCEVR-@DukeMargolis hosted symposium in Boston, "Celebrating Cost-Effectiveness Analysis."

Moderated by @AnkurFactorial

Register in person or online: https://t.co/OoD6YNXZzI @socmdm

[CEVR @TuftsCEVR]

We are thrilled to announce that pioneering #CEA researcher Milton C. Weinstein has joined Panel 2 at the 10/26 Tufts-CEVR / Duke Margolis symposium.

Register now!

In person: https://t.co/X09ZYozhFR

Webinar: https://t.co/WsaGPFDEVY

[CEVR @TuftsCEVR]

What does the future hold for CEA? Hear from experts @WrightCensored, @feralaes, @nlcrossnohere, and David Kim during Panel 5 at 10/26 Tufts-CEVR / Duke Margolis event.

Register now:

In-person: https://t.co/X09ZYozhFR

Webinar: https://t.co/WsaGPFDEVY

[Brian Reid @brianreid]

I am super-pumped at the prospect of collaborating with Peter and his team. We're living in a time of value, and I can't wait to contribute to the conversation.

[Peter Neumann @PeterNeumann11]

We are pleased to announce that @brianreid, a nationally-recognized expert in prescription drug policy and communications, has joined @TuftsCEVR as a Senior Fellow.

More here: https://t.co/FX9nLdwHUg #heor